Cargando…
A clinical prediction model identifies a subgroup with inferior survival within intermediate risk acute myeloid leukemia
Intermediate risk acute myeloid leukemia (AML) comprises around 50% of AML patients and is featured with heterogeneous clinical outcomes. The study aimed to generate a prediction model to identify intermediate risk AML patients with an inferior survival. We performed targeted next generation sequenc...
Autores principales: | Hu, Xiaoxia, Wang, Bianhong, Chen, Qi, Huang, Aijie, Fu, Weijia, Liu, Lixia, Zhang, Ying, Tang, Gusheng, Cheng, Hui, Ni, Xiong, Gao, Lei, Chen, Jie, Chen, Li, Zhang, Weiping, Yang, Jianmin, Cao, Shanbo, Yu, Li, Wang, Jianmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247394/ https://www.ncbi.nlm.nih.gov/pubmed/34234861 http://dx.doi.org/10.7150/jca.57231 |
Ejemplares similares
-
First case report of a NUP98-PMX1 rearrangement in de novo acute myeloid leukemia and literature review
por: Fu, Weijia, et al.
Publicado: (2021) -
PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia
por: Cheng, Hui, et al.
Publicado: (2017) -
The clinical impact of IKZF1 mutation in acute myeloid leukemia
por: Zhang, Xiang, et al.
Publicado: (2023) -
Sequential autologous and allogeneic stem cell transplantation for treatment of primary plasma cell leukemia: A case report
por: Fu, Weijia, et al.
Publicado: (2023) -
Human mesenchymal stem cells derived exosomes inhibit the growth of acute myeloid leukemia cells via regulating miR-23b-5p/TRIM14 pathway
por: Cheng, Hui, et al.
Publicado: (2021)